Publisher： Bentham Science Publishers
E-ISSN： 1873-4286|15|33|3867-3877
ISSN： 1381-6128
Source： Current Pharmaceutical Design, Vol.15, Iss.33, 2009-11, pp. : 3867-3877
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The hypoxia-inducible factor-1 (HIF-1) is a key regulator in the mammalian response to oxygen deficiency under both physiological and pathological conditions such as cancer. A number of studies indicated an association between tumor hypoxia, increased hypoxia-inducible factor (HIF-1) levels and a poor prognosis. The HIF-1 regulation in response to hypoxia occurs primarily on the level of protein stability due to posttranslational hydroxylation. However, HIF -subunits also respond to various growth factors, hormones, or cytokines under non-hypoxic conditions implicating the involvement of different kinase pathways in their regulation thereby increasing the interest in HIF-1 as a new drug target. Herein, we review current knowledge about phosphorylation-dependent HIF-1 regulation, HIF-1 protein-protein interactions and subcellular localization with emphasis on new therapeutic strategies targeting the HIF pathway.
Related content
Access to resources
Recommend
Calpains as potential anti-cancer targets
Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 3, 2011-03 ,pp. :
Protein Kinases as Drug Targets in Cancer
Current Cancer Drug Targets, Vol. 6, Iss. 7, 2006-11 ,pp. :
HIF Prolyl 4-Hydroxylases and their Potential as Drug Targets
Current Pharmaceutical Design, Vol. 15, Iss. 33, 2009-11 ,pp. :
ING Proteins as Potential Anticancer Drug Targets
Current Drug Targets, Vol. 10, Iss. 5, 2009-05 ,pp. :